Tempus AI secures $200 million five-year commitment from AstraZeneca
TEM•
TEM•Tempus AI secured a $200 million, five-year spending commitment from AstraZeneca, with a $32 million annual minimum. The renewal takes effect January 1, 2027, and extends the agreement through December 31, 2031.
Tempus AI signed a contract amendment with AstraZeneca on November 16, 2026, securing a $200 million spending commitment over five years. The renewal takes effect January 1, 2027, extending the master services agreement through December 31, 2031. AstraZeneca targets annual spending of $40 million across products and services, with a $32 million minimum each calendar year.
If AstraZeneca does not meet the aggregate commitment, the renewal will extend through December 31, 2032, to address the shortfall. AstraZeneca retains termination rights but must pay any shortfall against the $200 million commitment if it terminates for convenience.